Updated

Merck's CEO told CNBC that the company expects its breakthrough cancer vaccine will become faster and less expensive to produce, coinciding with the official opening of a new 120,000-square-foot research facility in the Greater Philadelphia area. The facility investment underscores Merck's commitment to scaling oncology innovation and accelerating the path to commercialization.